Free Trial

Ampio Pharmaceuticals Q3 2023 Earnings Report

Ampio Pharmaceuticals logo
$0.0026 0.00 (0.00%)
As of 01/21/2025 03:00 PM Eastern

Ampio Pharmaceuticals EPS Results

Actual EPS
-$1.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ampio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ampio Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Ampio Pharmaceuticals Earnings Headlines

Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
Ampio Pharmaceuticals, Inc. (AMPE)
See More Ampio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ampio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ampio Pharmaceuticals and other key companies, straight to your email.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

View Ampio Pharmaceuticals Profile

More Earnings Resources from MarketBeat